Opinion
Video
Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
Author(s):
Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.
EP: 1.Metastatic Prostate Cancer: Background and Patient Prognosis
EP: 2.Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer
EP: 3.Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life
EP: 4.Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis
EP: 5.Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer
Now Viewing
EP: 6.Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
EP: 7.Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer
Related Videos
Related Content
